(FINAL/APPROVED)

VIRGINIA BOARD OF PHARMACY

PUBLIC HEARING FOR POSSIBLE SCHEDULING CERTAIN CHEMICALS IN SCHEDULE I OF THE DRUG CONTROL ACT

September 25, 2019 Commonwealth Conference Center Second Floor Board Room 2 Department of Health Professions Perimeter Center 9960 Mayland Drive Henrico, Virginia 23233-1463

CALL TO ORDER:

The public hearing was called to order at 9:15 a.m.

PRESIDING:

Cynthia Warriner, Chairman

MEMBERS PRESENT:

Glenn L. Bolyard, Jr.
Melvin L. Boone, Sr.
Ryan K. Logan
Kristopher S. Ratliff
Patricia Richards-Spruill
Rebecca Thornbury

William Lee

James L. Jenkins, Jr.

STAFF PRESENT:

Caroline D. Juran, Executive Director Annette Kelley, Deputy Executive Director Ellen Shinaberry, Deputy Executive Director Elaine J. Yeatts, Senior Policy Analyst, DHP James Rutkowski, Assistant Attorney General

David E. Brown, DC, Director, DHP Kiara Christian, Executive Assistant

CALL FOR PUBLIC COMMENT:

Ms. Warriner called for comment to consider placement of the following chemicals into Schedule I.

Pursuant to article § 54.1-3443(D), the Virginia Department of Forensic Science (DFS) has identified nine (9) compounds for recommended inclusion into the Code of Virginia:

The following compounds are classified as powerful synthetic opioids:

- N-[2-(dimethylamino)cyclohexyl]-N-phenylfuran-2-carboxamide (other name: Furanyl UF17)
- N-[2-(dimethylamino)cyclohexyl]-N-

phenylpropionamide (other name: UF-17)

The following compounds are classified as research chemicals:

- 5-methoxy-N,N-dibutyltryptamine (other name: 5-methoxy-DBT)
- 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-butanone (other name: Eutylone, bk-EBDB)
- 1-(1,3-benzodioxol-5-yl)-2-(butylamino)-1-pentanone (other name: N-butylpentylone)
- N-benzyl-3,4-dimethoxyamphetamine (other name: N-benzyl-3,4-DMA)
- 3,4-methylenedioxy-N-benzylcathinone (other name: BMDP)

The following compounds are classified as cannabimimetic agents:

- Ethyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (other name: EMB-FUBINACA)
- Methyl 2-[1-4-fluorobutyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (other name: 4-fluoro-MDMB-BUTINACA)

If approved by the Board of Pharmacy, the placement of these substances into Schedule I shall go into effect 30 days following publication of the proposed regulation and remain in effect for a period of 18 months. The chemicals will then be de-scheduled unless a general law is passed by the General Assembly placing the chemicals into Schedule I.

PUBLIC COMMENT:

Scott May, Director of the Northern Virginia Lab, Department of Forensic Science offered comment on the identified chemicals. Because of a job promotion, he will no longer provide information to the board on this subject. He introduced the new Chemical Director who will assist the board in the future.

ADJOURN:

The public hearing adjourned at 9:20am.

Cynthia Warriner, Chairman

12-9-19

Date

Caroline D. Juran, Executive Director

1219119

Date